Aardvark Therapeutics, Inc. Common Stock AARD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$69.87M-152% | -$57.59M-180% | -$48.77M— | -$36.64M— | -$27.72M— | ||
| $42K+121% | $36K+125% | $34K— | $32K— | $19K— | ||
| $5.72M+845% | $3.95M+799% | $2.54M— | $1.19M— | $605K— | ||
| -$61.65M-126% | -$54.17M-200% | -$45.09M— | -$32.91M— | -$27.29M— | ||
| —— | $95K-12.8% | $101K— | $102K— | $104K— | ||
| —— | —— | —— | —— | -$124.62M— | ||
| $449K-99.7% | $89.32M+7.6% | $89.05M— | $88.94M— | $171.88M— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aardvark Therapeutics, Inc. Common Stock generate?
- Aardvark Therapeutics, Inc. Common Stock (AARD) generated -$61.7M in operating cash flow over the trailing twelve months.
- Where does Aardvark Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.